Hypertension Clinical Trials in Chicago

Showing 201-220 of 252 trials

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

NCT00409526

Inhaled Iloprost will be administered to near term infants with Persistent Pulmonary Hypertension of the Newborn in two different doses in order to test safety and efficacy in reducing pulmonary artery pressure.

Pulmonary Hypertension

University of Chicago1 participantsStarted Dec 2006

Chicago, Illinois, United States • Jerusalem, Israel

TERMINATEDPhase 32.2 miles

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00879229

Ambrisentan is an endothelin receptor antagonist used for the treatment of pulmonary hypertension (PH). Based on research suggesting a role for endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the poor prognosis for patients with IPF who are also diagnosed with PH, this study was designed to evaluate the effectiveness and safety of ambrisentan in that patient population.

Idiopathic Pulmonary FibrosisPulmonary Hypertension

Gilead Sciences40 participantsStarted Jul 2009

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Davis, California, United States +82 more locations

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Hypertension Trials in Other Cities

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

Sildenafil and Pulmonary Artery Pressure

REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch

Other Conditions in Chicago